Aureus Asset Management LLC Buys 2,298 Shares of Haleon plc (NYSE:HLN)

Aureus Asset Management LLC raised its position in Haleon plc (NYSE:HLN) by 18.3% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 14,881 shares of the company’s stock after buying an additional 2,298 shares during the period. Aureus Asset Management LLC’s holdings in Haleon were worth $157,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in HLN. FMR LLC boosted its holdings in Haleon by 5.8% in the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after acquiring an additional 5,768,117 shares during the last quarter. Clearbridge Investments LLC boosted its stake in shares of Haleon by 8.6% in the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after purchasing an additional 3,307,009 shares during the last quarter. Sculptor Capital LP grew its position in shares of Haleon by 67.8% during the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock worth $73,407,000 after buying an additional 3,592,000 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of Haleon by 2.7% during the second quarter. Envestnet Asset Management Inc. now owns 7,572,548 shares of the company’s stock worth $62,549,000 after buying an additional 196,843 shares during the last quarter. Finally, Raymond James & Associates lifted its holdings in Haleon by 14.7% in the second quarter. Raymond James & Associates now owns 4,019,978 shares of the company’s stock valued at $33,205,000 after buying an additional 515,651 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Trading Up 0.1 %

Shares of NYSE HLN opened at $9.67 on Tuesday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80. The company’s fifty day moving average is $9.92 and its 200-day moving average is $9.44. The stock has a market cap of $43.77 billion, a price-to-earnings ratio of 28.44, a P/E/G ratio of 2.92 and a beta of 0.30.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Berenberg Bank started coverage on shares of Haleon in a report on Tuesday, August 6th. They set a “buy” rating for the company. Morgan Stanley lifted their price objective on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. UBS Group raised Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Finally, The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Haleon has an average rating of “Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.